

## Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

## SCYNEXIS, Inc. Presents Ibrexafungerp Data at the 2018 ESCMID/ASM Conference on Drug Development

Sep 4 2018, 8:00 AM EDT

## SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

Aug 29 2018, 8:00 AM EDT

## SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

Aug 9 2018, 4:15 PM EDT

## Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	57.83m
Last Price	\$1.23
52-Week	\$1.05 - \$2.50

09/19/2018 04:00 PM EDT

## Investor Relations

Argot Partners  
Natalie Wildenradt  
T: 212-600-1902  
[natalie@argotpartners.com](mailto:natalie@argotpartners.com)

## Leadership

### Marco Taglietti, M.D.

President and Chief Executive Officer

### David Angulo, M.D.

Chief Medical Officer

### Eric Francois

Chief Financial Officer

### Scott Sukenick

General Counsel

---

## SCYNEXIS, Inc.

1 Evertrust Plaza  
13th Floor  
Jersey City, NJ 07302

---

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.